Salute e Benessere

Angelman Syndrome Market to Witness Significant Growth Through 2034, Driven by…

The condition is typically identified by developmental delays that become apparent between 6 and 12 months of age. Both males and females are equally affected, with the Angelman syndrome prevalence estimated to be about 1 in 12,000 to 20,000 people in the general population. The condition is typically identified by developmental delays that become apparent between 6 and 12 months of age. Both males and females are equally affected, with the Angelman syndrome prevalence estimated to be about1...
PR Newswire
02/06/2025

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare…

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and…
PR Newswire
02/06/2025

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates…

Media ReleaseCOPENHAGEN, Denmark; June 2, 2025 New data showed that rinatabart sesutecan (Rina-S ® ) 100 mg/m 2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response (mDOR) was not reached after a median follow-up of 7.7 monthsContinued evaluation of single-agent Rina-S 100 mg/m 2in patients with advanced endometrial cancer (EC) is ongoing in the Phase 2 RAINFOL™-01 trial and will be...
Nasdaq GlobeNewswire
02/06/2025

Full Dose-Escalation Data Show Continued High Response Rates and Favorable…

Safety profile continues to be favorable, with the majority of patients remaining on treatment at data cutoff Safety profile continues to be favorable, with the majority of patients remaining on treatment at data cutoff FDA recently granted ISB 2001 Fast Track Designation NEW YORK , June 2, 2025 /PRNewswire/ -- Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today presented...
PR Newswire
02/06/2025

OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer…

OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer Two presentations at the American Society of Clinical Oncology (ASCO) 2025:TEDOPaM - Phase 2 first positive results in advanced pancreatic cancer: Oral communication presented by the French GERCOR Oncology Group, trial sponsor.ARTEMIA- I nternational pivotal Phase 3 study in Non-Small Lung Cancer (NSCLC): Trial in Progress. ...
Nasdaq GlobeNewswire
02/06/2025

CRISPR Market is expected to generate a revenue of USD 12.78 Billion by 2032…

The CRISPR market is witnessing rapid growth due to its potential to transform gene therapy, diagnostics, and agriculture. With widespread research and commercial interest, the market is poised to shape the future of genomic healthcare. The CRISPR market is witnessing rapid growth due to its potential to transform gene therapy, diagnostics, and agriculture. With widespread research and commercial interest, the market is poised to shape the future of genomic healthcare. Key Highlights of the...
PR Newswire
02/06/2025

Medical Flexible Packaging Market Size worth $27.72 billion, Globally, by 2030-…

For More Information and To Stay Updated on The Latest Developments in The Medical Flexible Packaging Industry, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=10472 For More Information and To Stay Updated on The Latest Developments in The Medical Flexible Packaging Industry, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=10472 Market Overview and Growth Trajectory: Medical Flexible Packaging Industry Growth:...
PR Newswire
02/06/2025

HLA Typing Market worth US$2.3 billion by 2030 with 6.0% CAGR |…

Browse in-depth TOC on "HLA Typing Market" Browse in-depth TOC on "HLA Typing Market" 350 - Tables 52 - Figures 300 - Pages By Based on Product & Service,the reagents & consumables segment dominated the HLA typing market. Increasing emphasis on organ, tissue, and stem cell transplants is driving the demand for precise Human Leukocyte Antigen (HLA) matching considerably. This, in turn, is fueling enhanced use of reagents and consumables required for molecular and...
PR Newswire
02/06/2025

Medical Sensors Market Growth Forecast worth $142.2 billion, Globally, by 2030-…

For More Information and To Stay Updated on The Latest Developments in The Medical Sensors Market Share, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=8610 For More Information and To Stay Updated on The Latest Developments in The Medical Sensors Market Share, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=8610 Market Overview and Growth Trajectory: Medical Sensors Market Growth: According to an exhaustive...
PR Newswire
02/06/2025

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Global Healthcare Conference 2025, which will be held in New York, New York June 3-5, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer will deliver a presentation with recent business updates at the conference on Thursday...
Nasdaq GlobeNewswire
02/06/2025

Orexo to present clinical data for OX640 at the EAACI Congress

In addition to the oral presentation, Orexo's SVP and Head of R&D, Robert Rönn, will present a scientific poster demonstrating detailed stability data for OX640. In addition to the oral presentation, Orexo's SVP and Head of R&D, Robert Rönn, will present a scientific poster demonstrating detailed stability data for OX640. "We look forward to attending this important congress. Thanks to our powder-based drug-delivery technology, AmorphOX®, we are able to present strong data from…
PR Newswire
02/06/2025

Philanthropists and Business Leaders Gather in NY and London to Support…

The events will take place at two times: on June 3, from 8:30 a.m. to 11:30 a.m., at The Africa Center in New York, and on June 10, from 9:00 a.m. to 11:30 a.m., at The Royal Institution in London. On these occasions, the work of the Kianda Foundation will be presented to philanthropic leaders and businesspeople committed to gender equity. The events will take place at two times: onJune 3, from8:30 a.m. to 11:30 a.m., at The Africa Center inNew York, and onJune 10, from9:00 a.m...
PR Newswire
02/06/2025

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 2, 2025 – Genmab A/S (Nasdaq: GMAB).On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025.The following transactions were executed under the program from May 26 to May 30, 2025: Trading PlatformNo...
Nasdaq GlobeNewswire
02/06/2025

SkylineDx Highlights Merlin Assay's Power to Predict Recurrence Risk of Head and…

"The Merlin Assay is a major advancement in personalized care for patients with head and neck melanoma," said Principal Investigator, Teresa Amaral MD, PhD "SLNB can be technically challenging in the head and neck region. Merlin offers a powerful alternative for clinicians to make informed decisions without subjecting patients to unnecessary and potentially complicated surgical procedures." "The Merlin Assay is a major advancement in personalized care for patients with…
PR Newswire
02/06/2025

Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its…

Presentation at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21SIDNEY is an ongoing Phase 2 trial of EO2463 in 48 indolent Non-Hodgkin Lymphoma (iNHL) patientsEnterome has held a positive Type-C meeting with FDA for EO2463 in iNHLEnterome to attend Jefferies Healthcare conference in New York (June 3-5)Paris, France – June 2, 2025 Enterome SA,a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer,will...
Nasdaq GlobeNewswire
02/06/2025

Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput…

"Analytical laboratories are under pressure to adapt to the complex needs of pharmaceutical organizations, and meet the increasing demand for PFAS testing driven by a rapidly evolving regulatory landscape," said James Hallam, Vice President, Liquid Chromatography-Mass Spectrometry, Waters Corporation. "The Xevo TQ Absolute XR design delivers up to a six-fold increase in performance robustness with unmatched sensitivity and resilience to contamination, significantly reducing…
PR Newswire
02/06/2025

Endo Champions Men's Health Month with Education, Awareness, and Outreach

Key components of the campaign include: Key components of the campaign include: "Men may not always be the strongest advocates for their own health, but with the right information and awareness, we can empower them to take a more active role in their well-being," saidJustin Mattice, Senior Vice President & General Manager, Branded Specialty at Endo. "At Endo, we offer a unique portfolio of men's health products and equip healthcare providers with tools and education so they…
PR Newswire
02/06/2025

Novonesis completes acquisition of dsm-firmenichs's share of the Feed Enzyme…

Novonesis has successfully completed the acquisition of dsm-firmenich's share of the Feed Enzyme Alliance following the satisfaction of all closing conditions. The acquisition was initially announced on February 11, 2025 (announcement No 2).Please read the full announcement in PDF. Attachment 2025_Closing_of_the_Feed_Enzyme_Alliance
Nasdaq GlobeNewswire
02/06/2025

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

~ Alignment with FDA continues to support Accelerated Approval pathway ~~ BLA submission planned for first quarter of 2026 ~~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June02, 2025(GLOBE NEWSWIRE) --uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington's...
Nasdaq GlobeNewswire
02/06/2025

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico…

"Executing on our strategy of targeted acquisitions, Cialis® will expand our existing portfolio in the region and strengthen Grünenthal's Latin American business", says Gabriel Baertschi, CEO, Grünenthal. "In 2022, we acquired Nebido®, a long-acting treatment for testosterone deficiency, and with Cialis® we can continue to serve our existing customer base and foster our growth in key Latin American markets." "Executing on our strategy of targeted acquisitions, Cialis…
PR Newswire
02/06/2025

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab…

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged off-label bevacizumab in Europe each year 1 ISELIN, N.J., June02, 2025(GLOBE NEWSWIRE) --Outlook Therapeutics, Inc.(Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that...
Nasdaq GlobeNewswire
02/06/2025

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific…

"Alkermes is honored to present at these notable scientific meetings, sharing our research and insights with thought leaders and healthcare providers from across the field of psychiatry," said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President, Research & Development at Alkermes. "Alkermes is committed to contributing to the advancement of patient care and the body of evidence in neuro-psychiatry, including for the treatment of schizophrenia and bipolar…
PR Newswire
02/06/2025

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to…

BNT327, BioNTech's PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor typesThe co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners' expertise, resources and global footprint to accelerate BNT327's path towards potential regulatory approvals and market launches...
Nasdaq GlobeNewswire
02/06/2025

Transactions under Novonesis' share buyback program

Please read the announcement in PDF Attachment 2025_27_Share_buyback_program
Nasdaq GlobeNewswire
02/06/2025
Altri  Comunicati